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Abstract 
Shedding of Epstein-Barr virus (EBV) by astronauts before, during, and after pace shuttle 
missions was quantified. Of 1398 sa liva specimen from 32 a tronauts, 314 (23%) were positive 
for EBV DNA by PCR analysis. Of the saliva specimens collected before flight, 29% were 
positive for EBV DNA and of those collected during or after flight, 16% were EBV-positive. 
The number ofEBV D A copie from samples taken during the flight was 417 ± 31, 
significantly higher (P < 0.05) than the number of copies from the preflight (40 ± 1.7) and 
po tfli ght (44 ± 5) phases. Eighteen control subjects shed EBV D A with a frequency of 3.7% 
and a copy number of 40 ± 2 per ml ali va. Ten days before flight and on landing day, antibody 
titer to EBV viral capsid antigen (VCA) were ignificantly (P < 0.05) higher than baseline 
levels. On landing day, urinary level of corti 01 and catecholamines, and plasma levels of 
sub tance P and other neuropeptide , were increased over their preflight value. Results 
suggested that stress a ociated with spaceflight decrea es cel lular immunity and thereby leads to 
increased viral reactivation. 
Introduction 
Spaceflight i a unique and tressful environment for humans. Astronauts experience a wide 
pectrum of tres e , uch as i olation , confinement, fea r, anxiety, psychosocial issue , sleep 
deprivation , and mi crograv ity. The e stres ors may be intermittent or constant. Law 
enforcement officer, military per onnel, and others al 0 experience orne of these stres ors. 
However, microgravity is a unique and constant stre S, making paceflight an environment not 
duplicated anywhere on Earth. A wide range of physiological effects associated with 
paceflight, such as bone 10 ,mu cle atrophy, neurological anomalies, and cardiova cular 
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deconditi oning, have been reported and reviewed [1 -5] . The human immune respon e is also 
affected by spacefli ght. [6) Changes have been reported in whi te bl ood cell numbers, leukocyte 
and lymphocyte subsets, T-cell proli fe ration, cytokine production, natural kill er cell cytotoxici ty, 
and cell -medi ated immunity [7-11] . 
Gl aser and others [1 2] have shown that tres is associated with the onset, durati on, and inten ity 
of herpesv irus reactivati on. We have prev iously shown that reactivati on of Epstein-Barr virus 
(EBV), cytomegalov iru (CMV), and vari cell a-zo ter viru (VZV) increa es in astron auts 
parti cipating in space shuttle miss ions [1 3-15] . Psychological stre s has been implicated in the 
down-regulati on of the immune ys tem, and the response is medi ated, in part, through the action 
of tre hormone . The effect are remarkably simil ar to those seen in a tronauts after fl ight 
[16] . In a group of Antarctic exped itioners erv ing a a grou nd-ba ed mode l fo r spacefl ight, we 
showed th at increa ed shedding of EBV was concomitant with decreased cellular immunity 
[17] . T hi is con i tent with Gl a er et aI. ' [1 8] finding that antibody titers to the viral capsid 
antigen (VCA) of EBV increa ed with the dow n-regul ation of the cell ular immune re po nse in a 
tudent stress model. The increased EBV-specific antibody titer resulted fro m the memory B 
lymphocyte' re ponse to increased amou nt of viral protein after reactivation. W e observed 
imil ar increases in CM V antibodies in a tronauts, beginnin g with the preflight pha e and 
continuing durin g the fli ght and even during the fir t few day after landing [14] 
Prev iou studies showed that the incidence of EBV reactivati on in as tronaut was higher during 
the preflight pha e than e ither the in fl ight or postfl ight phase [13] . Thi contra ted with our 
f inding in Antarct ic expedi tioners, where the incidence was higher in the 8- to 9-month winter-
over isolation phase [17] . This tudy was undertaken to expand on our ini tial report of EBV 
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reactivation in astronauts [13J by determining the amount ofEBV shed during the three (before, 
during, and after) phases of a space huttle mission. 
Materials and Methods 
Subjects were 32 astronauts (24 men aged 37 through 57 year, mean = 44 years; 8 
women aged 32 through 47 years, mean = 39 years), all seropositive for EBY. They flew 
on 10 Space Shuttle missions of 9 to14 days duration. Two Ru sian cosmonauts 
participating in an 83-day mission aboard the Russian space station Mil' were also 
included in this study. Ba eline (prefli ght) aJiva ample were collected every other day 
for I to 2 months, beginning about 6 months before the flight. In-flight sali va samples 
were collected from crew members every day after their sleep period. Po tflight sample 
were collected on landing day (R+O) and every day for 2 weeks thereafter. Samples were 
coll ected in 1.0 ml of a biocidal torage buffer (1 % SDS, ] Om M Tris-CI, 1 mM EDT A) 
and stored at room temperature during the mis ion. Upon return of the sample to Earth, 
the saliva was collected by centrifugation and tored frozen until it wa processed. All 
amples co ll ected from each mission were analyzed s imultaneou ly. Ground-ba ed 
analysi verified the ability of the stability buffer to pre erve the viral D A for 
ubsequent PCR analysi [13] 
For mea urement of viral antibody titers and stres hormone levels, a I O-ml EDTA blood 
ample and a urine sample were co ll ected from each crew member 10 days before launch 
(L-lO), 2 to 3 hour after landing (R+O), and 3 days after landin g (R+3) . PI a ma wa 
separated by centrifugation and tored at -70°C until it was proces ed. All human study 
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protocol s were approved by the Committee for the Protection of Human Subjects of the 
Johnson Space Center. 
Control: Eighteeen healthy age-matched adults (14 male, 4 female) were included in 
this gro up. A sali va sample, a urine sample (1 0 ml), and a blood sample (10 ml , EDTA) 
were collected at 3 time points from all 18 subjects. The schedule of coJlection of the e 
samples mimicked the spaceflight (12-day) sample collection schedule (day 0 = L-I0, 
day 22 = R+O for a 12-day fli ght, and day 25 = R+3 . These samples were treated the 
same way a tho e of crew members to measure EBV DNA, antibody titer, and stress 
factor. 
Detection of EBV DNA 
Saliva specimens were concentrated with a lOOK f iltration unit (Filtron Technology 
Corp., orthborough, MA) and extracted by a nonorganic extraction method (Qiagen 
Inc., Chatsworth, CA). EBV wa detected with Digene Di agnostics, Gaithersburg, MD as 
de cribed earli er [1 3] , 
Quantitative estimation of EBV 
EBV copies were measured in po itive D A sample by using the Viral Quant EBV 
guantitative PCR detection kit (Biosource International, CA), A known number of copies 
of exogenou synthesized D A intern al calibration standard (ICS) were mixed with 
sample D A before it wa extracted and amplified, The rcs has been constructed to 
contain a PCR primer binding site identical to that of EBV DNA and a unigue capture 
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binding site that allows the resulting ICS ampli con to be distinguished from the viral 
ampJicon. EBV DNA wa ampli fied with Viral Quant format primer, one of which is 
biotinylated. These primers target a conserved equence of EBER L The EBERl gene is 
expressed during EBV latency as a small nonpolyadenyl ated RNA transcribed by RNA 
pol IlL Sequence recogn ized by the two EBV -specific amplification primers are 
identical for the type 1 and type 2 trains of EBY. After PCR was perfonned, the 
amplicon were denatured and hybridized to e ither ICS or EBV sequence-specific capture 
oligonucleotides. Details are given elsewhere [19] 
Measurement of EBV antibody titer 
The titers of antibodies to EBV antigens VCA and early antigen (EA) were determined 
by indirect immunofluore cence assay (IFA) in the plasma samples collected from crew 
members 10 day before f li ght, at landing, and 3 day after landing. Titers of antibodies 
to EBV-VCA were also determined in sample archived from the annual physical 
exami nat ions of the a tronaut , which served a the baseline. These measurements were 
also carri ed out on the samples collected from 18 controls. Commercial ly-prepared 
sub trate lide and control era were used for determining EBV IgG and measles IgG 
antibody titer (Bion Enterpri es, Park Ridge, II..,) . Tenfold dilutions of plasma were 
prepared with PBS. The endpoint titer was determined as the highest dilution of serum 
giving immunofluore cent cell. A ll pecimen were batch analyzed and read blind-
coded. 
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Stress honnones 
Plasma cortisol, adrenocorticotropic hormone (ACTH), and human growth hormone 
(HGH), and urinary cortisol , norepinephrine, and epinephrine were measured by 
radioimmunoassay [20, 21] in the samples collected from a tronauts before and after 
paceflight. 
Neuropeptides 
The neuropeptide ubstance P, calcitonin gene-related peptide, neuropeptide Y, and 
vasoactive inte tinal peptide were measured in plasma from the 5 astronauts who 
participated in one of the 10 space shuttle flights included in the study. They were 
measured in ampJe collected] ° day before the flight, 2 to 3 hours after Janding, and 3 
day after landing by a receptor-affinity chromatographic technique coupled with 
immunological detection [22] 
Statistical analysis 
To te t whether EBV activation wa ign if icantl y increased during flight we first expressed each 
ubj ect's in-flight EBV cop ie as a difference from hi Iher pre-flight average. Next, this change in 
EBV cop ies wa regressed on time in f li ght (day) using generali zed e timating equations in a 
gener~llinear model etting [23] with a normal family. In the process, standard errors were 
obtained u ing the Huber-White" andwich" estimator [24, 25] to account for repeated 
measurement on some ubject at different times during flight; for example, one subj ect's EBV 
count wa measured on nine different days. After fitting the regression mode l, we tested the null 
hypothe is of no increa ed acti vati on any time during flight, which i equivalent to both the 
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intercept and the slope of the regress ion line being zero . Confidence limits for both the slope and 
intercept were also obtained. 
Results 
EBV DNA was detected in 22.5% of the saliva ample (3 14/1398) collected from 32 
as tron auts before, during, or after 10 paceflights (Table 1). Thi s rate was significantly 
hi gher (P < 0.05) than the 3.7% EBV-positive amples from the 18 control subjects. Of 
the aliva specimen collected about 6 months before flight, 29.1 % were positive for 
EBV D A. Of those coll ected during and after spaceflight EBV was positive in 15.7% 
and 15 .5% samples respectively . Control values over a period simulating a J 2-day pace 
shuttle mi ion did not vary ignificantly. 
The di stribution of EBV copies found before, during, and after the fli ght is shown in 
Figure 1. Although the frequency of EBV DNA was nearly 2-fold greater in the samples 
co llected before f li ght than in those collected at other times, the number of copies of EBV 
DNA was ignificantly (P < 0.05) higher (aboLlt 10-fold) in the sampl es collected during 
flight than in preflight or postflight ample. The number of EBV copies (mean per ml 
ali va ± SE) wa 40.3 ± 1.7 before, 417.2 ± 3 ] .J during, and 44.3 ± 5.4 after fli ght. The 
medi an of the number of EBV copies detected in ali va samples increased as the duration 
of flight increased. The e timated equation for Y, (the increase in EBV count) is Y = 23.9t +215, 
where t is flight time in day. The test of the null hypothe is of no increase at any time during 
fli ght wa overwhelmingly rejected (P < .0000 1), that is, there wa a ignificant increase in EBV 
copies during flight than pre or post f li ght. In add ition the rate of increased EBV copies per day 
of fli ght (23.9) wa significantl y greater than zero (P = 0.00013) that is, as the durati on of flight 
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increases, EBV copies increase significantl y. Ninety-fi ve percent confidence limits fo r the daily 
increa e were 11 .6 and 36. 1. 
The durations of these space shuttl e missions ranged from 9 to 14 days. Two Russian 
cosmonauts partic ipating in an 83-day mission aboard the Ru sian pace station Mil' had 
similar EBV sheddin g pattern s and an increased number ofEBV copies during the fli ght 
phase. The mean number of EBV copies per ml of sali va was 24.7 ± 3.9 before the fli ght 
and 18.8 ± 6.9 after the fl ight. During the long fli ght the number ofEBV copies soared 
to 4S] ± 79.3. These data, shown in F igure 2, were d iv ided in to th ree group , f ir t 
group, 21 to 40 days; econd group , 4 1 to 60 days; and third, 61 to 7S days. The number 
of EBV copies wa hi ghest during the fir t and the third group during the fl ight. 
Shuttle a tronaut VCA antibody ti ter at 10 days before launch (L-I0), at landing (R+O), 
and 3 days after landing (R+3) were ign ificantl y increa ed (P < 0.001 ) from the ba eline 
va lue taken 5 to 24 month before f li ght (Figure 3). Ti ters were the same at L- IO and 
R+O, but increa ed further at R+3 (P < 0.001 ). As expected, no significant change was 
observed in the titer of anti bodi e to EBV earl y antigen (EA). A a control, we measured 
mea Ie IgG antibody titer and fOLlIld no change from baseline levels throughout the 
tudy in terval. The VCA IgG antibody titers of 18 control subj ect were simil ar to the 
a tro naut baseline levels and did not change acro the 3 sampling times . 
Stress hormones were measured at three time points, one before launch (L-I0) and two 
after land ing (R+O and R+3) (Figure 4). The level of cortisol in pl asma was not 
signi ficantly lower after landing than before fl ight, but plasma levels of insulin and 
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aldo terone increased (Panel A). Pl asma ACTH and HGH did not change. Levels of 
corti 01, epinephrine, and norepinephrine in urine at R+O were significantly hi gher than at 
L-IO (Panel B) (p<O.05). The control had no such changes during the study period. 
Neuropeptides were measured in plasma of 5 crew members before and after a s-day 
flight. Levels of substance P (SP), calcitonin gene-related peptide (CGRP), neuropeptide 
Y (NY), and vasoactive intestinal peptide (VIP) were ignificantly hi gher (p<O.05) 
(Figure 4) at R+O than at L-lO. However, 3 days after landing, only SP showed a further 
increase which was statisticall y in ignificant. CGRP, Y, and VIP either showed no 
further increa e from their R+O levels or declined. In case of control group, these changes 
were not ob erved. 
Discussion 
This study is a fo llow-up of our ini tial finding that a tronaut shed EBV befo re, during, and 
immedi ately after spacefli ght [1 3] . We previou Iy found that the shedding frequency was 
higher during the preflight phase than during e ither the flight or po tfli ght pha e . The 
current tudy confirmed that f inding. The major objective wa to determine if the number 
of copie of viral DNA correlated with shedding frequency. We quantifi ed the amount of 
EBV hed in a tronauts' a li va during all three phase of pace huttl e mi ions. Although 
the frequency of EBV shedd ing in ali va wa hi gher before fl ight, the number of EBV 
copies wa ] O-fold hi gher during the flight phase. Thi s indicates that the intensity or 
combination of stre ors experi enced by astronauts whil e they are in pace may be 
re ponsible fo r the increa ed EBV D A in sali va. The data (Figures . 1 and 2) also 
indicated that the number ofEBV copie increase as a function of day in space . Saliva 
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amples from cosmonauts aboard the Russ ian space station Mir for 83 days contained more 
cop ies of EBV D A than saliva samples from the US a tronauts particularly in space flight 
missions of 14 days or less. Also, the peak number of EBV copies (1130/ml) in amples 
f rom cosmonauts wa hi gher than the maximum number of copies (738/ml) in samples 
from US astronauts. Taken together, data from the short-term and long-term space 
mi ions indicate that the numbers of EBV shed in sali va may increa e with increasing 
time in space. 
Glaser [18 , 26, 27] and others have tudied EBV reactivation in several tress model and 
fou nd increased reactivation ofEBV as mea ured by increases in anti body titers to VCA. 
Gl aser et al. [1 2,28] also showed that reactivation of EBV was a function of the type of 
tress. For example, physical stre sa ociated with basic training of We t Point cadets did 
not resu lt in EBV reactivation. However, tress a soc iated with final examinations resulted 
in ubstantial viral reactivation. Consi tent with their work, we have fo und that VCA ti ters 
increase before flight and continue to increase through 3 day after fli ght. This indicates 
that astronauts are exposed to substantial levels of various stre sors, reSUlting in EBV 
reactivation beginning well before fli ght. 
Exami ning hormone profile provided fu rther evidence of stre exposure . Urinary levels 
of cortisol and the catecholam ines were sign ificantl y higher after flight than before flight. 
These data were consistent with re ults from the Skylab mi ions [29] and previous space 
huttl e mi sion [14, 30] . Cortisol, ep inephrine, and norepi nephrine in urine are usually 
increased at landing, probably as a con equence of the stresses associated with the reentry 
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and landing process. Plasma levels of cortisol at landing were not elevated over preflight 
values. The peak plasma level of cortisol, which has a circadian rhythm, may have occurred 
before or after the sample wa collected. Plasma corti 01, which has a short (-4-hour) half-
life, was co llected only once before and once after spacefl ight, giving a "snapshot" look at 
plasma levels , whereas each urinary cortisol value was obtained from a pool of urine 
col lected over a 24-hour period. The "snap hot" of pIa ma cortisol may have missed 
transient but significant changes that were detected in urine, which provided an integration 
of 24 hour of collection[30] . All of the neuropeptides mea ured eSp, VIP, Y, and 
CGRP), were elevated immediately after landing. Only SP had increa ed even more by 3 
days after landing. Increa ed VIP, SP, and CGRP levels have been associated with 
decreased cellular immunity [31 , 32] . Similarly, increased levels of Y have been fou nd 
in chronic tress ubjects [33] . Until the neuropeptide data from the 5 astronaut can be 
expanded to a larger number of participants, the significance of changes in neuropeptide 
levels cannot be adequately asse sed. However, the e findings are consistent with data 
from Antarctic expeditioners and astronauts. We previously demonstrated decreased 
cellular immunity in Antarctic expeditioner during a stre sful 8-9 month winter-over 
period at the Au tral ian Antartic science stations [17] . Taylor et al. [6] demonstrated 
decreased cell -mediated immunity in a tronauts during spaceflight. 
The viral hedding patterns, vim -specific antibody titer re ponse, increases in stress 
hormone , and increa ed level of neuropeptides lead us to draw some conclu ions. No 
correlation wa observed between increased viral reactivation and age, sex, flight 
experience or nature of the duties (e.g., pilot vs. non pilot) of the crew member. 
A tronauts are exposed to multiple stre sor capable of reactivating EBV before, during, 
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and after flight aboard the space shuttle. The intensity or combination of stressors during 
the flight may vary significantly from the stres or experienced before or after the flight. 
Our data indicate that more EBV is hed in saliva during spaceflight than during the 
ground pha e of preparing for the mission and recovering from spaceflight-a sociated 
stress . The increased amount of EBV DNA in saliva, coup led with the propen ity of large 
and small saliva droplets to float in the microgravity of the crew compartment, may lead 
to increased ri k of cross infection among crew members . One would expect minimal 
medical effect of such events in healthy individuals , but the effectivenes of the immune 
respon e of a tronauts has been que tioned [6] . 
Studies are in progress to determine if the increased reactivation of EBV in 
astronauts is a general effect extending to other human herpes viruses, and 
if it produce any health effects in a tronaut on pace missions longer 
than 14 days. 
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Figure 1. EBV copies/ml saliva in 32 astronauts before, during, and after 10 space shuttle missions. 
Figure 2. EBV copies/ml saliva in crew members before, during, and after an 83-day mission aboard 
the Russian space station Mir . 
Figure 3. Viral IgG antibody titers (log2 mean + SE) in astronauts at Baseline 
(BL), 10 days before launch (L-10), at landing (R+O) , and 3 days after landing (R+3) . 
EA titers were not available at BL. 
Figure 4 . Stress hormones measured in plasma (panel A) and urine (panel B) in the 32 astronauts 
before and after space flights 
Figure 5. Neuropeptides (mean + SE) in astronauts before and after a 5-day mission 
10 days before launch (L-10), at landing (R+O), and 3 days after landing (R+3). 
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